Press Releases
May 18, 2023
Satsuma Pharmaceuticals Announces FDA Acceptance of 505(b)(2) NDA for STS101, a Novel and Investigational Dihydroergotamine (DHE) Nasal Powder Product for the Acute Treatment of Migraine
Apr 21, 2023
Innovative
Therapeutics for
Better Health
Because Life
Shouldn't Have to
Wait for Migraines